Sugi Predict

Sugi Predict / Compounds / SCHEMBL2403560

SCHEMBL2403560

SCHEMBL2403560

O=C(O)c1cc(-c2cc(Cl)ccc2O)ccc1O

nearest known ligand 0.76

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CA1 P00915 3/20 0.76
▸ CA2 P00918 3/20 0.76
▸ LCK P06239 2/20 0.57
▸ ACMSD Q8TDX5 7/20 0.56
▸ MCL1 Q07820 7/20 0.56
▸ DHFR P00374 2/20 0.56
▸ HNF4A P41235 1/20 0.56
▸ ALDH1A1 P00352 2/20 0.54
▸ KDM4E B2RXH2 1/20 0.54
▸ MEN1 O00255 1/20 0.54
▸ USP2 O75604 1/20 0.54
▸ LMNA P02545 1/20 0.54
▸ TTR P02766 1/20 0.54
▸ ALB P02768 1/20 0.54
▸ HMGB1 P09429 1/20 0.54
▸ HPGD P15428 1/20 0.54
▸ CXCL12 P48061 1/20 0.54
▸ KMT2A Q03164 1/20 0.54
▸ HIF1A Q16665 1/20 0.54
▸ SLC22A6 Q4U2R8 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2406306 0.92 CA1 (0.62) CA1CA2LCKACMSDMCL1
5-Chlorosalicylic Acid SCHEMBL130605 0.87 CA1 (1.00) CA1CA2ACMSDMCL1DHFR
5-Chlorosalicylic Acid SCHEMBL29499764 0.87 CA1 (1.00) CA1CA2ACMSDMCL1DHFR
SCHEMBL412559 0.87 CA1 (0.71) CA1CA2LCKACMSDMCL1
5-Chlorosalicylic Acid SCHEMBL6855770 0.85 CA1 (0.96) CA1CA2ACMSDMCL1DHFR
5-Chlorosalicylic Acid SCHEMBL27653684 0.85 CA1 (0.96) CA1CA2ACMSDMCL1DHFR
5-Chlorosalicylic Acid SCHEMBL943143 0.85 CA1 (0.96) CA1CA2ACMSDMCL1DHFR
5-Chlorosalicylic Acid SCHEMBL27673709 0.85 CA1 (0.96) CA1CA2ACMSDMCL1DHFR
5-Chlorosalicylic Acid SCHEMBL11158036 0.85 CA1 (0.96) CA1CA2ACMSDMCL1DHFR
5-Chlorosalicylic Acid SCHEMBL27653659 0.85 CA1 (0.96) CA1CA2ACMSDMCL1DHFR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040019190-A1 Thrombopoietin mimetics NOVARTIS AG (CH) 2004-01-29 — — US claimed
US-20150093356-A1 THROMBOPOIETIN MIMETICS GLAXOSMITHKLINE LLC 2015-04-02 — — US disclosed
US-20130078213-A1 THROMBOPOIETIN MIMETICS GLAXOSMITHKLINE LLC 2013-03-28 — — US disclosed
US-20110212054-A1 THROMBOPOIETIN MIMETICS GLAXOSMITHKLINE LLC. 2011-09-01 — — US disclosed
US-7790704-B2 Thrombopoietin mimetics GlaxoSmithKline, LLC (US) 2010-09-07 — — US disclosed
US-7674887-B2 Thrombopoietin mimetics GLAXOSMITHKLINE LLC (US) 2010-03-09 — — US disclosed
US-7648971-B2 Thrombopoietin mimetics SMITHKLINE BEECHAM CORP. (US) 2010-01-19 — — US disclosed
EP-1889838-B1 Thrombopoietin mimetics SMITHKLINE BEECHAM CORP (US) 2009-10-14 — — EP disclosed
US-20090176746-A1 THROMBOPOIETIN MIMETICS SMITHKLINE BEECHAM CORPORATION 2009-07-09 — — US disclosed
US-20090176973-A1 THROMBOPOIETIN MIMETICS SMITHKLINE BEECHAM CORPORATION AND GLAXO GROUP LIMITED 2009-07-09 — — US disclosed
EP-1889838-A1 Thrombopoietin mimetics SmithKline Beecham Corporation (US) 2008-02-20 — — EP disclosed
US-7332481-B2 Thrombopoietin mimetics SMITHKLINE BEECHAM CORPORATION (US) 2008-02-19 — — US disclosed
EP-1864981-A1 Thrombopoietin mimetics SmithKline Beecham Corporation (US) 2007-12-12 — — EP disclosed
US-20070179192-A1 THROMBOPOIETIN MIMETICS SMITHKLINE BEECHAM CORPORATION AND GLAXO GROUP LIMITED 2007-08-02 — — US disclosed
US-20070129338-A1 THROMBOPOIETIN MIMETICS SMITHKLINE BEECHAM CORPORATION 2007-06-07 — — US disclosed
US-7160870-B2 Thrombopoietin mimetics SMITHKLINE BEECHAM CORPORATION (US) 2007-01-09 — — US disclosed
US-20040019190-A1 Thrombopoietin mimetics NOVARTIS AG (CH) 2004-01-29 — — US disclosed
EP-1294378-A4 THROMBOPOIETIN MIMETICS SMITHKLINE BEECHAM CORP (US) 2004-01-28 — — EP disclosed
EP-1294378-A2 THROMBOPOIETIN MIMETICS SMITHKLINE BEECHAM CORPORATION (US) 2003-03-26 — — EP disclosed
WO-2001089457-A2 THROMBOPOIETIN MIMETICS SMITHKLINE BEECHAM CORPORATION (US) 2001-11-29 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070129338-A1 THROMBOPOIETIN MIMETICS MPL, THPO, TEK CA1 4586/4885CA2 4818/4885LCK 1313/4885
US-20070179192-A1 THROMBOPOIETIN MIMETICS MPL, THPO, TEK CA1 4586/4885CA2 4818/4885LCK 1313/4885
US-20150093356-A1 THROMBOPOIETIN MIMETICS MPL, THPO, TEK CA1 4586/4885CA2 4818/4885LCK 1313/4885
US-20090176746-A1 THROMBOPOIETIN MIMETICS MPL, THPO, TEK CA1 4586/4885CA2 4818/4885LCK 1313/4885
US-20110212054-A1 THROMBOPOIETIN MIMETICS MPL, THPO, TEK CA1 4586/4885CA2 4818/4885LCK 1313/4885
US-20130078213-A1 THROMBOPOIETIN MIMETICS MPL, THPO, TEK CA1 4586/4885CA2 4818/4885LCK 1313/4885
US-20090176973-A1 THROMBOPOIETIN MIMETICS MPL, THPO, TEK CA1 4586/4885CA2 4818/4885LCK 1313/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.